271 related articles for article (PubMed ID: 36121081)
1. Neurological Complications of SARS-CoV-2 Infection and COVID-19 Vaccines: From Molecular Mechanisms to Clinical Manifestations.
Yepes M
Curr Drug Targets; 2022; 23(17):1620-1638. PubMed ID: 36121081
[TBL] [Abstract][Full Text] [Related]
2. Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders?
Murta V; Villarreal A; Ramos AJ
ASN Neuro; 2020; 12():1759091420954960. PubMed ID: 32878468
[TBL] [Abstract][Full Text] [Related]
3. Myoclonus status revealing COVID 19 infection.
Ben Mohamed D; Zouari R; Ketata J; Nabli F; Blel S; Ben Sassi S
Seizure; 2023 Jan; 104():12-14. PubMed ID: 36446232
[TBL] [Abstract][Full Text] [Related]
4. Neurological consequences of COVID-19.
Brola W; Wilski M
Pharmacol Rep; 2022 Dec; 74(6):1208-1222. PubMed ID: 36180640
[TBL] [Abstract][Full Text] [Related]
5. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
6. An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine.
Davoudi F; Miyashita S; Yoo TK; Lee PT; Foster GP
Crit Pathw Cardiol; 2022 Sep; 21(3):123-129. PubMed ID: 35994720
[TBL] [Abstract][Full Text] [Related]
7. Role of aging in Blood-Brain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19.
Adesse D; Gladulich L; Alvarez-Rosa L; Siqueira M; Marcos AC; Heider M; Motta CS; Torices S; Toborek M; Stipursky J
Fluids Barriers CNS; 2022 Aug; 19(1):63. PubMed ID: 35982454
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between SARS-CoV-2 Infection and Neurological Disorders: A Review.
Azhar A; Wali MA; Rashid Q; Khan WH; Al-Hosaini K; Owais M; Kamal MA
CNS Neurol Disord Drug Targets; 2023; 22(5):643-658. PubMed ID: 35440321
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication.
Abdel Moneim A; Radwan MA; Yousef AI
Curr Med Res Opin; 2022 Jul; 38(7):1071-1079. PubMed ID: 35575011
[TBL] [Abstract][Full Text] [Related]
10. Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted.
Borah P; Deb PK; Chandrasekaran B; Goyal M; Bansal M; Hussain S; Shinu P; Venugopala KN; Al-Shar'i NA; Deka S; Singh V
Front Mol Biosci; 2021; 8():627723. PubMed ID: 33681293
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm that Implicates for Therapeutic Strategies.
Chong ZZ; Souayah N
Curr Med Chem; 2022; 29(12):2051-2074. PubMed ID: 33970839
[TBL] [Abstract][Full Text] [Related]
12. Neurological manifestations of COVID-19: with emphasis on Iranian patients.
Aslan C; Nikfarjam S; Asadzadeh M; Jafari R
J Neurovirol; 2021 Apr; 27(2):217-227. PubMed ID: 33710597
[TBL] [Abstract][Full Text] [Related]
13. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).
Beeraka NM; Tulimilli SV; Karnik M; Sadhu SP; Pragada RR; Aliev G; Madhunapantula SV
Biomed Res Int; 2021; 2021():8160860. PubMed ID: 34159203
[TBL] [Abstract][Full Text] [Related]
14. The Impact of COVID-19 and Vaccine on the Human Nervous System.
Chen F; Cao P; Liu H; Cai D
Neuroendocrinology; 2022; 112(11):1046-1057. PubMed ID: 35316815
[TBL] [Abstract][Full Text] [Related]
15. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.
Dewanjee S; Vallamkondu J; Kalra RS; Puvvada N; Kandimalla R; Reddy PH
Mol Neurobiol; 2021 Sep; 58(9):4694-4715. PubMed ID: 34169443
[TBL] [Abstract][Full Text] [Related]
16. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients.
Crunfli F; Carregari VC; Veras FP; Silva LS; Nogueira MH; Antunes ASLM; Vendramini PH; Valença AGF; Brandão-Teles C; Zuccoli GDS; Reis-de-Oliveira G; Silva-Costa LC; Saia-Cereda VM; Smith BJ; Codo AC; de Souza GF; Muraro SP; Parise PL; Toledo-Teixeira DA; Santos de Castro ÍM; Melo BM; Almeida GM; Firmino EMS; Paiva IM; Silva BMS; Guimarães RM; Mendes ND; Ludwig RL; Ruiz GP; Knittel TL; Davanzo GG; Gerhardt JA; Rodrigues PB; Forato J; Amorim MR; Brunetti NS; Martini MC; Benatti MN; Batah SS; Siyuan L; João RB; Aventurato ÍK; Rabelo de Brito M; Mendes MJ; da Costa BA; Alvim MKM; da Silva Júnior JR; Damião LL; de Sousa IMP; da Rocha ED; Gonçalves SM; Lopes da Silva LH; Bettini V; Campos BM; Ludwig G; Tavares LA; Pontelli MC; Viana RMM; Martins RB; Vieira AS; Alves-Filho JC; Arruda E; Podolsky-Gondim GG; Santos MV; Neder L; Damasio A; Rehen S; Vinolo MAR; Munhoz CD; Louzada-Junior P; Oliveira RD; Cunha FQ; Nakaya HI; Mauad T; Duarte-Neto AN; Ferraz da Silva LF; Dolhnikoff M; Saldiva PHN; Farias AS; Cendes F; Moraes-Vieira PMM; Fabro AT; Sebollela A; Proença-Modena JL; Yasuda CL; Mori MA; Cunha TM; Martins-de-Souza D
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2200960119. PubMed ID: 35951647
[TBL] [Abstract][Full Text] [Related]
17. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19).
Harapan BN; Yoo HJ
J Neurol; 2021 Sep; 268(9):3059-3071. PubMed ID: 33486564
[TBL] [Abstract][Full Text] [Related]
18. Manifestations and mechanisms of central nervous system damage caused by SARS-CoV-2.
Yang F; Zhao H; Liu H; Wu X; Li Y
Brain Res Bull; 2021 Dec; 177():155-163. PubMed ID: 34571039
[TBL] [Abstract][Full Text] [Related]
19. Neuro-COVID-19: an insidious virus in action.
Bratosiewicz-Wąsik J
Neurol Neurochir Pol; 2022; 56(1):48-60. PubMed ID: 34642927
[TBL] [Abstract][Full Text] [Related]
20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
